Universal activity biomarker independent of activation pathway
Measuring TCC levels can be very informative as a supplement to functional assessment of the three complement pathways. As a product of the terminal pathway, TCC can be a result from all three complement activation pathways, and reflects the total in vivo activity of complement.
Enabling effective treatment
Increased levels of TCC can be detected in both acute injury and inflammation like trauma and sepsis and in chronic inflammation and diseases like atypical hemolytic uremic syndrome (aHUS), Systemic lupus erythematosus (SLE), ANCA associated vasculitis and rheumatoid arthritis (RA).
Preventing adverse reactions
The complement system can also be activated by artificial surfaces, for example during hemodialysis or cardiopulmonary bypass, resulting in increased levels of TCC. TCC is therefore well suited for studies of complement activation by biomaterials in medical devices and part of the recommended tests for assessing complement activation according to ISO standard 10993-4 for hemocompatibility testing.